|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
GENE THERAPY
From the Divisions of Clinical Research and Human
Biology, Fred Hutchinson Cancer Research Center; and the Department of
Medicine, University of Washington School of Medicine, Seattle, WA.
Previous studies have shown that the choice of envelope
protein (pseudotype) can have a significant effect on the efficiency of
retroviral gene transfer into hematopoietic stem cells. This study used
a competitive repopulation assay in the dog model to evaluate
oncoretroviral vectors carrying the envelope protein of the endogenous
feline virus, RD114. CD34-enriched marrow cells were divided into equal
aliquots and transduced with vectors produced by the RD114-pseudotype
packaging cells FLYRD (LgGLSN and LNX) or by the gibbon ape leukemia
virus (GALV)-pseudotype packaging cells PG13 (LNY). A total of 5 dogs
were studied. One dog died because of infection before sustained
engraftment could be achieved, and monitoring was discontinued after 9 months in another animal that had very low overall gene-marking levels.
The 3 remaining animals are alive with follow-ups at 11, 22, and 23 months. Analyses of gene marking frequencies in peripheral blood and
marrow by polymerase chain reaction revealed no significant differences between the RD114 and GALV-pseudotype vectors. The LgGLSN vector also
contained the enhanced green fluorescent protein (GFP), enabling us to
monitor proviral expression by flow cytometry. Up to 10% of peripheral
blood cells expressed GFP shortly after transplantation and
approximately 6% after the longest follow-up of 23 months. Flow
cytometric analysis of hematopoietic subpopulations showed that most of
the GFP-expressing cells were granulocytes, although GFP-positive
lymphocytes and monocytes were also detected. In summary, these results
show that RD114-pseudotype oncoretroviral vectors are able to transduce
hematopoietic long-term repopulating cells and, thus, may be useful for
human stem cell gene therapy.
(Blood. 2001;98:2065-2070) The hematopoietic compartment is a particularly
attractive target for the introduction of therapeutic genes because of
its accessibility, potential for massive expansion and self-renewal, and availability of well-established technologies for manipulation ex
vivo. Retroviral vectors have been the most commonly employed means of
gene transfer in clinical gene therapy trials because they have the
potential to integrate into the host genome to provide durable
transgene expression in target cells. However, although very high gene
transfer rates were obtained in murine hematopoietic stem cells,
similarly high transduction efficiencies have not been reproduced in
large animal models or human trials.
In recent years modifications in transduction conditions have led to
improved retrovirus-mediated gene transfer into hematopoietic repopulating cells in large animals such as nonhuman
primates1-4 or dogs.5,6 These changes
included use of fibronectin fragment CH-296, addition of cytokine
combinations with activity in early hematopoietic cells, and use of the
gibbon ape leukemia virus (GALV) pseudotype. Although initial gene
transfer efficiencies of more than 20% were achieved, long-term levels
usually declined to between 0.1% and 5%. For most clinical gene
therapy applications, however, higher gene transfer levels will be required.
A key feature of retroviral transduction is the binding of viral
envelope protein to specific cell surface proteins. This interaction
determines the range of cells that can be transduced by a given viral
vector. In addition, efficient transduction by retrovirus vectors
requires high-level expression of the appropriate cell surface virus
receptor.7-10 Previous studies in dogs and nonhuman
primates have shown that the use of the GALV envelope (GALV-pseudotype)
resulted in superior transduction of hematopoietic repopulating cells
compared with the amphotropic pseudotype. This observation correlated
well with the demonstration that the GALV receptor Pit1 is more
abundantly expressed than the amphotropic receptor Pit2 in
CD34+ hematopoietic cells.1,6
An alternative viral pseudotype based on the feline endogenous
retrovirus RD114 has been described.11 Vectors bearing the RD114 envelope have been shown to transduce human hematopoietic cells
at high efficiency.12-14 On the basis of these studies we wanted to investigate whether RD114-pseudotype vectors would improve gene transfer rates into hematopoietic stem cells compared with the
widely used GALV-pseudotype vectors. To demonstrate the effect of
titer, we used a low-titer-producing FLYRD clone, providing titers in
the range of PG13 cells, as well as a high-titer-producing FLYRD
clone, which produced up to 29-fold higher titers. This experimental
design allowed us to compare high and low titers within one packaging
system and between 2 different packaging cell lines. With the use of a
canine competitive repopulation assay, we have directly examined
whether RD114-pseudotype vectors would increase gene transfer rates.
Animals
Retrovirus vectors and cell lines
Production of virus-containing medium Packaging cells were plated at a density of 5 × 104/mL per 15-cm dish (Corning, Corning, NY). When cells reached 90% confluency, medium was replaced with fresh Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS; GIBCO-BRL) and 1% Pen/Strep (GIBCO-BRL). After further incubation at 37°C for 12 to 16 hours, supernatant was collected and filtered through 0.45-µm pore size filters (Nalge Nunc International, Rochester, NY) before freezing and storing at 70°C.
Endpoint titer determination On day 0, 5 × 104 D17 or HT1080 cells were plated in 6-well plates (Corning) in DMEM. After incubation for 24 hours, the medium was replaced by fresh DMEM supplemented with 10% FBS, 1% Pen/Strep, and Polybrene 4 µg/mL. The cells were then infected with 100 µL diluted vector supernatant (10 1 to
104 serial dilutions). After 24 hours of exposure to the
virus, medium was removed, and the cells were trypsinized and split
1:10 in 4 mL DMEM containing G418 (0.5 mg/mL). At day 5, the
G418-containing medium was renewed to maintain the G418 activity. At
day 12, or when nontransduced control D17 cells were completely dead,
colonies were stained by using Coomassie blue and enumerated by using
an inverted microscope. The endpoint titer (colony forming unit
[CFU]/mL) was calculated by averaging the colony numbers per well
after multiplication by the dilution factor.
CD34 enrichment of bone marrow cells The method used has been described previously.6,17 Briefly, bone marrow mononuclear cells were separated by a Ficoll gradient and labeled with biotinylated monoclonal antibody 1H6 (immunoglobulin G1 anti-canine CD34) 40 µg/mL at 4°C for 30 minutes. The cells were washed twice, incubated with streptavidin-conjugated microbeads for 30 minutes at 4°C, washed, and then separated by using an immunomagnetic column technique according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA).Transduction of enriched bone marrow cells CD34-enriched cells were prestimulated for 24 hours in Iscoves modified Dulbecco medium supplemented with 12.5% horse serum (GIBCO-BRL), 12.5% FBS (GIBCO-BRL), 106 M hydrocortisone
(Sigma Chemical, St Louis, MO), 104 M 2-mercaptoethanol
(Sigma), 1% glutamine, 1% penicillin/streptomycin (GIBCO-BRL) in the
presence of FLT3-ligand (FLT3-L; Immunex, Seattle, WA), canine stem
cell factor, and canine granulocyte-colony-stimulating factor (Amgen)
at a concentration of 50 ng/mL. After prestimulation, equal numbers of
CD34-enriched cells were placed in 75-cm2 canted-neck
flasks (Corning) coated with CH-296 (RetroNectin; Takara Shuzo, Japan)
at a concentration of 2 µg/cm2. Fresh
retrovirus-containing medium was replaced 4 times over a period of 48 hours, in addition to cytokines (50 ng/mL) and protamine sulfate (8 µg/mL). After transduction, nonadherent and adherent cells were
pooled, counted, and infused intravenously into the animal within 24 hours of total body irradiation.
PCR analysis Genomic DNA was prepared using proteinase K (Sigma) as described.6 Amplification conditions for LNY and LNX vectors have been described6 and were also used for LgGLSN. Briefly, 300 ng genomic DNA was amplified with SN 2257 and ASN 3210 primers by using 0.5 U Taq polymerase (GIBCO-BRL). Conditions were optimized to produce linear amplification in the range of intensity of the positive PCR samples: denaturation at 95°C, followed by 26 to 28 cycles (depending on gene marking levels) of 64°C annealing (1 minute), and 95°C denaturation (1 minute) with a final extension at 72°C for 7 minutes. For the detection of LN, LNX, and LNY, PCR was performed in the presence of 10 mCi/mL (370 MBq/mL) 32P deoxycytidine triphosphate, and PCR products were separated on a 6% polyacrylamide gel. To correct for different amounts of DNA in the templates, the -actin gene was amplified in
duplicates of 100 ng and 300 ng genomic DNA with the following primers:
actin-1, 5' TCC TGT GGC ATC CAC GAA ACT 3'; and actin-2, 5' GAA GCA TTT GCG GTG GAC GAT 3'. PCR conditions for the amplification of -actin were the same as for the neo gene, except that only 24 cycles were performed. Phosphor image analysis was used to quantify PCR signal intensities by comparing PCR signals in DNA from peripheral blood with PCR signals in DNA from a dilution series of single-vector copy HT1080/LN, -LNX, and -LNY cells. Calculated gene transfer percentages were corrected for the number of experimental arms and
assume that peripheral blood cells contain an average of one copy of
the corresponding vector per cell. For the analysis of hematopoietic
subpopulations, DNA from T cells, granulocytes, and monocytes was
isolated. Cell separations were performed by using monoclonal
antibodies and a fluorescence-activated cell sorter (FACSVantage;
Becton Dickinson, San Jose, CA). Granulocytes were purified by using
the monoclonal antibody DM5,18 which recognizes a canine
myeloid antigen. CD3+ T cells were purified by using
canine-specific anti-CD3 antibody, CA17.2A12 (provided by Dr Peter
Moore, University of California, Davis, CA), and monocytes were
isolated by using a human anti-CD14 antibody (DAKO,
Carpinteria, CA).
Flow cytometric analysis Flow cytometric quantification of at least 20 000 propidium iodide (1 µg/mL) excluding forward and right-angle light scatter-gated events was performed on a FACSCalibur (Becton Dickinson). Analysis of flow cytometric data was performed with the use of CELLQuest v3.1f software with gating to exclude 0.01% control
cells in the relevant region. Monoclonal antibodies conjugated to
phycoerythrin, which had been shown to bind canine CD markers CD3 and
CD14, were used to study canine T cells and monocytes, and DM5 was used
to examine dog granulocytes. Gene transfer levels were corrected for
the number of experimental arms used in the different dogs.
Northern blot analysis RNA was prepared from 1 to 3 × 107 NIH3T3, FLYRD, HT 1080, and D17 cells by using Trizol (GIBCO-BRL). For Northern blot analysis, 10 µg total RNA per sample was separated in a 1.2% agarose gel containing 2.2 M formaldehyde and transferred to a nitrocellulose filter (Hybond-N+, Buckinghamshire, England). Membranes were hybridized at 65°C to RDR19 or Pit1 probes that had been radiolabeled with -32P dCTPs, using a random
priming kit (Random Primed DNA Labeling Kit; Boehringer-Mannheim,
Germany). Both probes had identical specific activities of
1 × 106 cpm/µg DNA. Filters were exposed to phosphor
image screens for 72 hours and analyzed using Image Quant software
(Molecular Dynamics, Sunnyvale, CA). After analysis filters were
stripped using 0.5% sodium dodecyl sulfate and reprobed using the
second probe.
Detection of helper virus After transplantation, peripheral blood mononuclear cell DNA was assayed for the presence of recombinant helper virus genomes by envelope-specific PCR by using identical conditions to those used for amplification of the neo gene. Positive control log dilutions of DNA from PG13/LN packaging cells into normal dog DNA were quantified concurrently. The sequences of the primers used to amplify the GALV envelope gene have been described previously.1 The sequences of the primers used to amplify the RD114 envelope gene were as follows: Rde324F, 5' CCA GGA CAT CCA CAA ACT AGC C 3'; Rde792R, 5' GTC TTG CCT CCG CAA GTT ACC 3'. The detection limit using this approach was approximately 1 copy per 10 000 cells. PCR analyses of peripheral blood samples for the presence of GALV and RD114 envelope sequences were negative in all animals, indicating the absence of helper-virus infection.
CD34 enrichment and engraftment of transduced cells We employed a competitive repopulation assay to study gene transfer efficiency into canine repopulating cells by using RD114-pseudotype retrovirus vectors. Five dogs were transplanted with transduced CD34-enriched autologous marrow cells to compare gene transfer efficiencies with LgGLSN (FLYRD) and LNY (PG13). In the first 3 animals a RD114-pseudotype vector (LNX) with a lower titer as compared with LgGLSN (RD114) was also included to determine the influence of titer and multiplicity of infection (MOI) on gene transfer.Cell yield, purity, and recovery after CD34 enrichment are summarized
in Table 1. After
transplantation, one animal died because of infection before sustained
leukocyte engraftment was achieved (E668). In the 4 surviving animals a
stable absolute neutrophil count of > 500/µL was reached at a
median of 17 days (range, 10-23 days), and a platelet count of
> 50 000/µL was reached at a median of 58 days (range, 43-76 days). Neither the purity of enriched CD34 cells nor total cell number
was predictive of the duration of thrombocytopenia. Monitoring was
discontinued after 9 months in the animal with lowest overall
transduction rate (E737). The remaining 3 dogs are now at 11, 22, and
23 months after transplant and healthy.
Ex vivo gene transfer efficiency in hematopoietic progenitors CD34-enriched bone marrow cells were prestimulated and divided into 3 equal fractions. Then each fraction was transduced with the different vectors. In 3 dogs (E668, E523, and E695), the different fractions were transduced with LNY (PG13), LNX (FLYRD), and LgGLSN (FLYRD). In 2 additional dogs (E737 and E760), cells were divided into only 2 fractions and transduced with LNY and LgGLSN. Vector titers were measured on D17 cells. Because of the differences in titers, mean MOIs for the transduction of CD34-enriched cells were 1.2 (0.2-1.7), 3.8 (2.1-5), and 25.6 (3.8-37) for LNY, LNX, and LgGLSN, respectively (Table 2).
In all instances cells transduced with the GALV-pseudotyped virus expanded more (on average 1.62-fold) than the cells transduced with the RD114-pseudotype virus (on average 1.22-fold), although that difference was not statistically significant. Expression rates were determined by flow cytometry in fractions
transduced with GFP-containing vector LgGLSN (FLYRD). Gene transfer
efficiency in these CD34-enriched cells was between 69% and 94%
(Figure 1, Table 1). To exclude
pseudotransduction (ie, GFP protein transfer from the virus-containing
medium) as a possible explanation for the high gene transfer rates by
flow cytometry, we transduced canine D17 cells with vector-containing
medium from FLYRD/LgGLSN and measured GFP expression over time. After
an initial increase during the first 2 days following transduction, GFP
expression levels remained constant for more than 14 days (data not
shown), suggesting that the initial gene transfer rates as determined by flow cytometry were indeed from integrated virus and not because of
pseudotransduction.
In vivo comparison between the GALV- and RD114-pseudotype vectors In all 5 animals gene transfer efficiencies were compared between the high-titer RD114-pseudotype vector LgGLSN and the GALV-pseudotype vector LNY. In 3 of the 5 animals, a low-titer RD114-pseudotype vector (LNX) was included; the titer of this vector was similar to the titer of the GALV-pseudotype vector. Gene transfer rates after transplantation were measured by flow cytometry (for LgGLSN only) and by PCR (for all vectors used) of peripheral blood leukocytes. In contrast to the high-titer vector, the low-titer RD114-pseudotype vector performed significantly worse compared with the GALV-pseudotype vector even though both vectors had similar titers on D17 cells. These results suggest that higher titer viruses will be required for efficient transduction using RD114-pseudotype vectors produced by FLYRD. The use of the low-titer RD114-psuedotype vector LNX also resulted in significantly inferior gene transfer compared with the high-titer RD114-pseudotype vector LgGLSN (P < .0002), indicating that vector concentration is important for efficient gene transfer into hematopoietic repopulating cells using FLYRD-derived vectors. Representative analyses of 2 dogs (E523 and E695) are shown in Figure 2. In E695 and E760 the use of LgGLSN led to slightly higher gene transfer levels compared with the PG13-derived vector. In E737, the overall gene transfer rate was low, and only LgGLSN was detected between 0.1% and 0.01%. In E668 the gene transfer levels for LNY were higher than for LgGLSN with very short follow-up, and in E523 no difference between the 2 vectors was detected. To demonstrate successful gene transfer into primitive multipotential hematopoietic cells, peripheral blood cells from 3 dogs were enriched using fluorescence-activated cell sorting for granulocytes (DM-5), T lymphocytes (CD 3), and monocytes (CD14). The presence of all 3 vectors was demonstrated by PCR in granulocytes, T lymphocytes, and monocytes in all 3 dogs. Figure 3 shows the PCR results from E523 at 27 and 49 weeks after transplant. In summary, 4 of 5 dogs demonstrated at least equivalent gene transfer efficiency using the high-titer RD114-pseudotype vector compared with the GALV-pseudotype vector.
Analysis of GFP expression in peripheral blood cells after transplantation Because one of the RD114-pseudotype vectors (LgGLSN) contained the GFP gene, expression from integrated vector could be measured by flow cytometry. Figure 4 provides a summary of GFP expression in peripheral blood samples over time in 4 of the 5 animals. In the fifth dog, E737, gene transfer was very low and GFP expression could not be detected. In the other 4 dogs initial expression levels between 4% and 10% were achieved. However, within the first 10 to 15 weeks after transplantation expression declined to a baseline level between 1% and 7%, which has been sustained for 1 to almost 2 years in 3 dogs.
To assess gene expression in specific hematopoietic lineages,
peripheral blood cells in long-term expressing dogs were labeled with
monoclonal antibodies against granulocytes (DM-5), T lymphocytes (CD3),
and monocytes (CD14) and were analyzed by flow cytometry at different
time points. Figure 5 summarizes the
results in the 3 dogs. Sustained GFP expression was detected in all
subsets examined. Very similar patterns of GFP expression in
subpopulations were seen at different time points after transplantation
(data not shown). The percentage of GFP-expressing cells was generally
higher in granulocytes (up to 8.1%) than in T lymphocytes (up to
3.5%) or monocytes (up to 5.7%). Two animals were examined for GFP
expression in platelets and were found to have between 1.2% and 1.3%
GFP-positive platelets at 9 and 21 months after transplant. We were not
able to detect GFP in erythrocytes.
Northern analysis of retroviral receptor expression To determine whether titer differences observed between the RD114- and the GALV-pseudotype vectors could be a consequence of retroviral receptor expression and to compare receptor levels in cells of human and canine origin, we analyzed messenger RNA levels of GALV and RD114 receptor on different cell lines. Expression levels of Pit1 were comparable to the RD114 receptor (RDR) in D17 cells, which was in contrast to human cell lines (HT1080, FLYRD), in which Pit1 expression was more abundant than RDR expression (data not shown). These findings indicate that the titer differences observed between RD114- and GALV-pseudotype vectors on D17 and HT1080 cells were not because of differential expression of Pit1 and RDR.
The low gene transfer efficiency into hematopoietic long-term repopulating cells has been a major obstacle in the application of stem cell-based gene therapy. A significant barrier to efficient transduction with the widely used GALV-pseudotype or amphotropic vectors has been the relatively low-level expression of retroviral receptors Pit1 and Pit2 on hematopoietic stem/progenitor cells.1,10 In this study we used a competitive repopulation assay in the dog to evaluate an alternative viral pseudotype based on the feline endogenous retrovirus RD114. We have shown that RD114-pseudotype vectors produced by FLYRD were able to transduce long-term repopulating cells in lethally irradiated dogs. GFP-positive peripheral blood granulocytes, lymphocytes, monocytes, and platelets have been detected for almost 2 years to date, indicating that RD114-pseudotype vectors can transduce true multipotential hematopoietic stem cells. In all 5 dogs studied we compared transduction efficiency of RD114-pseudotype vectors with that of the GALV-pseudotype vector. All 3 vectors used in this study contained the neo gene, and one of the RD114-pseudotype vectors (LgGLSN) also contained the GFP gene. Thus, the comparison between the RD114-pseudotype vectors and GALV-pseudotype vector was based on PCR analysis of the different neo signatures in the different vectors. The high-titer RD114-pseudotype vector resulted in a marginally superior gene transfer efficiency in long-term repopulating cells. However, the overall gene transfer levels were not markedly different from dogs that received CD34-enriched cells transduced by GALV-pseudotype vectors in this study or in previous studies.5,6 Although we achieved long-term marking of, and gene expression in, hematopoietic stem cells using RD114-pseudotype vectors, the in vivo gene transfer levels after hematopoietic reconstitution were significantly lower than transduction rates in CD34+ cells as determined by flow cytometric analysis before infusion into the animal. It is unlikely that the high gene transfer levels demonstrated before infusion were due to pseudotransduction because we demonstrated constant GFP expression levels over an extended period of time in cells transduced by RD114-pseudotype vectors. A more likely explanation for this discrepancy is the recently described effect of the conditioned medium generated from the RD114-pseudotype FLYRD packaging cells on hematopoietic progenitor/stem cells. Kelly et al13 have shown that conditioned medium from HT1080 cells, which is the parental cell line used to generate FLYRD cells, led to the differentiation of primitive hematopoietic cells and subsequent loss of engraftment in the nonobese diabetic/severe combined immunodeficiency model. We did not analyze the phenotype of our transduced CD34-enriched cells; however, the number of culture colony-forming units recovered after transduction from the different experimental arms was consistently lower after transduction with LgGLSN (FLYRD) compared with the GALV-pseudotype vector LNY (data not shown), suggesting the loss of more primitive cells under these culture conditions. This finding would also suggest that engraftment of RD114-transduced cells, and thus gene transfer levels in the dog, could be considerably improved by using modified transduction conditions, including the avoidance of exposure to the HT1080-conditioned medium as described by Kelly et al.13 Alternatively, other human packaging cells could be used to generate RD114-pseudotype vectors. There is evidence that vectors produced by human 293 cells may be superior to vectors produced by murine packaging cells, which have been shown to produce inhibitory factors.20-22 In 3 of the dogs we included a third experimental arm by using a RD114-pseudotype vector from a low-titer FLYRD clone. The titer differences between the high-titer FLYRD/LgGLSN and the low-titer FLYRD/LNX cells were up to 29-fold. This finding resulted in a marked difference in the gene transfer rates in vivo between the 2 vectors, suggesting that a higher MOI facilitated the transduction of canine repopulating cells. It is important to note that, although titers for the PG13-derived LNY vector were similar to the low-titer RD114-pseudotype vector, transduction efficiency in vivo was substantially higher with the PG13-derived vectors. These data suggest that, although titers and MOI are important, comparisons can only be made within one packaging system. Moreover, high-titer vector appears to be required for efficient transduction of hematopoietic-repopulating cells by RD114-pseudotype vectors, although we have not ruled out the possibility that the low-titer RD114 producer cell line was generating an increased amount of noninfectious particles that could have competed with the same receptor and thereby interfered with transduction. The titer differences observed on D17 and HT1080 cells between the high-titer RD114-pseudotype and the GALV-pseudotype vector were not due to differences in the corresponding receptor expression, because expression of Pit1 and RDR were comparable in D17 cells, and Pit1 was even more abundant in HT1080 cells than RDR. After an initial decline in GFP-positive cells, we have observed stable persistence of gene-modified cells for almost 2 years at last assessment. The initial decline was most likely due to transduced progenitor cells and not due to gene silencing because we saw a similar decline when peripheral blood cells were analyzed for the presence of the transgene by PCR. The possible development of an immune response against GFP-containing cells is an unlikely explanation for the initial decline because GFP-positive cells remained detectable at stable levels for almost 2 years. In conclusion, our data show stable transduction of canine hematopoietic repopulating cells by using RD114-pseudotype oncoretroviral vectors. The fact that we were able to detect gene-modified cells in multiple lineages for almost 2 years to date suggests that the RD114-pseudotype was able to mediate transduction of a true multipotential hematopoietic stem cell. In light of high gene transfer rates observed in human progenitor cells and nonobese diabetic/severe combined immunodeficiency repopulating cells and the more abundant expression of the RD114 receptor on human cells as compared with dog cells, the application of RD114-pseudotype vectors offers a promising alternative in human stem cell gene therapy.
We thank Eric Bell, Alix Smith, Lori Ausburn, the technicians of the Canine Shared Resource, the hematology and pathology laboratories for their technical assistance, and Bonnie Larson and Helen Crawford for assistance with the preparation of the manuscript. We also thank Drs Peter McSweeney, Brenda Sandmaier, and Peter Moore for providing us with canine antibodies used in this study.
Submitted January 23, 2001; accepted May 14, 2001.
Supported in part by grants HL36444, DK47754, and DK56465 from the National Institutes of Health. M.G. and P.A.H. are supported by the German Krebshilfe. J.E.J.R. was supported by Fellowship DRG081 of the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation. H.P.K. is a Markey Molecular Medicine Investigator.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D1-100, PO Box 19024, Seattle, WA 98109-1024; e-mail: hkiem{at}fhcrc.org.
1.
Kiem H-P, Heyward S, Winkler A, et al.
Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons.
Blood.
1997;90:4638-4645
2.
Kiem H-P, Andrews RG, Morris J, et al.
Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor.
Blood.
1998;92:1878-1886
3.
Dunbar CE, Seidel NE, Doren S, et al.
Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.
Proc Natl Acad Sci U S A.
1996;93:11871-11876
4.
Tisdale JF, Hanazono Y, Sellers SE, et al.
Ex vivo expansion of genetically marked Rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability.
Blood.
1998;92:1131-1141 5. Kiem H-P, McSweeney PA, Bruno B, et al. Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector. Gene Ther. 1999;6:966-972[CrossRef][Medline] [Order article via Infotrieve].
6.
Goerner M, Bruno B, McSweeney PA, Buron G, Storb R, Kiem H-P.
The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs.
Blood.
1999;94:2287-2292
7.
Kurre P, Kiem H-P, Morris J, Heyward S, Battini J-L, Miller AD.
Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor.
J Virol.
1999;73:495-500 8. Orlic D, Girard LJ, Anderson SM, et al. Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. Stem Cells. 1997;15(suppl 1):23-28.
9.
Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM.
The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.
Proc Natl Acad Sci U S A.
1996;93:11097-11102 10. Kurre P, Morris J, Miller AD, Kiem H-P. Envelope fusion protein binding studies in an inducible model of retrovirus receptor expression and in CD34+ cells emphasize limited transduction at low receptor levels. Gene Ther. 2001;8:593-599[CrossRef][Medline] [Order article via Infotrieve]. 11. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MKL. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol. 1995;69:7430-7436[Abstract].
12.
Onodera M, Nelson DM, Yachie A, et al.
Development of improved adenosine deaminase retroviral vectors.
J Virol.
1998;72:1769-1774
13.
Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF.
Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein.
Blood.
2000;96:1206-1214 14. Porter CD, Collins MK, Tailor CS, et al. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther. 1996;7:913-919[Medline] [Order article via Infotrieve].
15.
Bauer TR Jr, Miller AD, Hickstein DD.
Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines using retroviral vectors having a gibbon ape leukemia virus envelope.
Blood.
1995;86:2379-2387
16.
Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV.
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.
J Virol.
1991;65:2220-2224
17.
McSweeney PA, Rouleau KA, Wallace PM, et al.
Characterization of monoclonal antibodies that recognize canine CD34.
Blood.
1998;91:1977-1986 18. Sandmaier BM, Schuening FG, Bianco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5:125-130[Medline] [Order article via Infotrieve].
19.
Rasko JEJ, Battini J-L, Gottschalk RJ, Mazo I, Miller AD.
The RD114/simian type D retrovirus receptor is a neutral amino acid transporter.
Proc Natl Acad Sci U S A.
1999;96:2129-2134 20. Forestell SP, Dando JS, Chen J, de Vries P, Bohnlein E, Rigg RJ. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther. 1997;4:600-610[CrossRef][Medline] [Order article via Infotrieve]. 21. Davis JL, Witt RM, Gross PR, et al. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther. 1997;8:1459-1467[Medline] [Order article via Infotrieve]. 22. Le Doux JM, Morgan JR, Snow RG, Yarmush ML. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol. 1996;70:6468-6473[Abstract].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  E. Verhoeyen and F.-L. Cosset Engineering the Surface Glycoproteins of Lentiviral Vectors for Targeted Gene Transfer CSH Protocols, August 1, 2009; 2009(8): pdb.top59 - pdb.top59. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Kawai, U. Choi, L. Cardwell, S. S. DeRavin, N. Naumann, N. L. Whiting-Theobald, G. F. Linton, J. Moon, P. M. Murphy, and H. L. Malech WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4 Blood, January 1, 2007; 109(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Kiem, J. Allen, G. Trobridge, E. Olson, K. Keyser, L. Peterson, and D. W. Russell Foamy virus-mediated gene transfer to canine repopulating cells Blood, January 1, 2007; 109(1): 65 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Bauer Jr, M. Hai, L. M. Tuschong, T. H. Burkholder, Y.-c. Gu, R. A. Sokolic, C. Ferguson, C. E. Dunbar, and D. D. Hickstein Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy Blood, November 15, 2006; 108(10): 3313 - 3320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Sorrentino Improved human stem-cell transduction: the cat's meow Blood, July 1, 2005; 106(1): 8 - 8. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Lucas, N. E. Seidel, C. D. Porada, J. G. Quigley, S. M. Anderson, H. L. Malech, J. L. Abkowitz, E. D. Zanjani, and D. M. Bodine Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes Blood, July 1, 2005; 106(1): 51 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Neff, B. C. Beard, L. J. Peterson, P. Anandakumar, J. Thompson, and H.-P. Kiem Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy Blood, February 1, 2005; 105(3): 997 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hanawa, P. Hematti, K. Keyvanfar, M. E. Metzger, A. Krouse, R. E. Donahue, S. Kepes, J. Gray, C. E. Dunbar, D. A. Persons, et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system Blood, June 1, 2004; 103(11): 4062 - 4069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Horn, K. A. Keyser, L. J. Peterson, T. Neff, B. M. Thomasson, J. Thompson, and H.-P. Kiem Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol Blood, May 15, 2004; 103(10): 3710 - 3716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Morris, M. Conerly, B. Thomasson, J. Storek, S. R. Riddell, and H.-P. Kiem Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning Blood, January 15, 2004; 103(2): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brenner, N. L. Whiting-Theobald, G. F. Linton, K. L. Holmes, M. Anderson-Cohen, P. F. Kelly, E. F. Vanin, A. M. Pilon, D. M. Bodine, M. E. Horwitz, et al. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/{beta}2-microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells Blood, October 15, 2003; 102(8): 2789 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Neff, P. A. Horn, V. E. Valli, A. M. Gown, S. Wardwell, B. L. Wood, C. von Kalle, M. Schmidt, L. J. Peterson, J. C. Morris, et al. Pharmacologically regulated in vivo selection in a large animal Blood, August 28, 2002; 100(6): 2026 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sandrin, B. Boson, P. Salmon, W. Gay, D. Negre, R. Le Grand, D. Trono, and F.-L. Cosset Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates Blood, July 18, 2002; 100(3): 823 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Walters, A. W. Nienhuis, and E. Vichinsky Novel Therapeutic Approaches in Sickle Cell Disease Hematology, January 1, 2002; 2002(1): 10 - 34. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
